Provided by Tiger Trade Technology Pte. Ltd.

Arvinas Holding Company LLC

9.37
+0.34003.77%
Post-market: 9.370.00000.00%19:30 EDT
Volume:951.75K
Turnover:8.84M
Market Cap:612.34M
PE:70.06
High:9.39
Open:9.02
Low:9.00
Close:9.03
52wk High:14.51
52wk Low:6.97
Shares:65.39M
Float Shares:56.67M
Volume Ratio:1.77
T/O Rate:1.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.1337
EPS(LYR):-1.1400
ROE:1.59%
ROA:-1.01%
PB:1.09
PE(LYR):-8.21

Loading ...

Arvinas Inc: Arv-102 Was Well Tolerated Across All Dose Levels Following 28 Days of Once-Daily Dosing

THOMSON REUTERS
·
Mar 18

Arvinas Inc - Plans Phase 1B Trial of Arv-102 in Psp in Q2 2026

THOMSON REUTERS
·
Mar 18

Arvinas Inc - No Serious Adverse Events, Discontinuations, or Deaths Reported With Arv-102

THOMSON REUTERS
·
Mar 18

Arvinas to Present Phase 1 ARV-102 Data at AD/PD 2026 Conference

Reuters
·
Mar 11

Piper Sandler Sticks to Their Buy Rating for Arvinas Holding Company (ARVN)

TIPRANKS
·
Mar 06

Arvinas Is Maintained at Buy by Citigroup

Dow Jones
·
Mar 06

Arvinas price target raised to $18 from $15 at Citi

TIPRANKS
·
Mar 05

Analysts Conflicted on These Healthcare Names: Xenon (XENE), Arvinas Holding Company (ARVN) and Esperion (ESPR)

TIPRANKS
·
Mar 04

Arvinas Holding Company (ARVN) Gets a Hold from Morgan Stanley

TIPRANKS
·
Feb 27

Regulatory Turbulence: How FDA Disruptions and Budget Cuts Threaten Arvinas Holding Company’s Drug Development Timelines

TIPRANKS
·
Feb 26

Stephens Sticks to Its Buy Rating for Arvinas Holding Company (ARVN)

TIPRANKS
·
Feb 25

Arvinas Is Maintained at Neutral by Wedbush

Dow Jones
·
Feb 25

Barclays Reaffirms Their Buy Rating on Arvinas Holding Company (ARVN)

TIPRANKS
·
Feb 25

Arvinas FY 2025 net loss narrows to USD 80.8 million (59.4%)

Reuters
·
Feb 25

Arvinas price target raised to $11 from $9 at Wedbush

TIPRANKS
·
Feb 25

Wedbush Lifts Price Target on Arvinas to $11 From $9, Keeps Neutral Rating

MT Newswires Live
·
Feb 25

Arvinas Publishes Corporate Presentation on PROTAC Protein Degraders for Cancer and Neurodegenerative Diseases

Reuters
·
Feb 24

Earnings Flash (ARVN) Arvinas Posts Q4 Net Loss $1.10 a Share, vs. FactSet Est of $0.51 Loss

MT Newswires Live
·
Feb 24

Arvinas Q4 EPS $(1.10) Misses $(0.55) Estimate, Sales $9.500M Miss $34.879M Estimate

Benzinga Earnings
·
Feb 24

Arvinas Q4 revenue misses; names Randy Teel as CEO

Reuters
·
Feb 24